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Congenital muscular dystrophy (CMD) due to merosin (laminin a2 chain) deficiency is an autosomal recessively inherited
disorder characterized by severe muscular weakness and hypotonia from birth on. Brain involvement is the rule and characterized
by variable T2 hyperintensities of white matter which appears swollen on cranial MRI. The pathophysiology of these white matter
changes is not clear. In five patients with laminin a2 deficient CMD we performed short-echo time localized proton MRS with
determination of absolute metabolite concentrations in grey and white matter. In affected white matter, a consistent pattern of
metabolites was detected comprising reduced concentrations of N-acetylaspartate and N-acetylaspartylglutamate, creatine, and
phosphocreatine, and to a milder degree of choline-containing compounds. In contrast, concentrations of myo-inositol were in
the normal range. Spectra of cortical and subcortical grey matter were normal. The observed metabolite profile is consistent with
white matter edema, that is reduced cellular density, and relative astrocytosis. This interpretation is in line with the hypothesis that
laminin a2 deficiency results in leakage of fluids across the blood–brain barrier and a histopathological report of astrocytic
proliferation in CMD.
 2006 Elsevier B.V. All rights reserved.
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Laminin, a complex glycoprotein found extracellu-
larly in the basement membranes, consists of three
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Kassel, Kassel, Germany.two light chains, b and c. They are bound to each
other by disulfide bonds forming a cross-shaped mole-
cule. The alpha-2 (a2) chain is a subunit of laminin-2
(merosin) and laminin-4 (s-merosin). Laminin is
thought to mediate the attachment, migration, and
organization of cells into tissues during embryonic
development by interacting with other extracellular
matrix components. Tissues containing laminin com-
prise placenta, striated and cardiac muscle, peripheral
nerve, meninges, chorioid plexus, and other regions
of the brain [1]. In 1994, a lack of merosin, the
laminin a2 chain, was demonstrated in patients with
the classical non-Fukuyama type congenital muscular
dystrophy (CMD) [2]. Subsequently, mutations in the
LAMA2 gene on chromosome 6q22–q23 were detected
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MIM #607855) [3].
Clinical features in complete deficiency of laminin a2
include severe muscular hypotonia and weakness in the
first weeks of life with slow improvement, but inability
of independent ambulation in most cases [4]. Congenital
contractures are common, feeding difficulties and respi-
ratory problems may occur. Creatine kinase levels are
markedly raised. Extramuscular involvement includes
demyelinating peripheral neuropathy and striking white
matter changes on cranial MRI. Widespread diffuse T2
hyperintensity of swollen appearing white matter is a
characteristic finding after the first months of life [5].
Some of the patients have macrocephaly. However,
clinical symptoms of cerebral involvement are usually
rather mild. Intelligence is normal in most children,
and epilepsy may occur in about 30% of patients [4].
In few patients, a range of structural malformations
was demonstrated comprising occipital agyria, poly-
microgyria, and hypoplasia of pons and vermis clinically
accompanied by more severe mental and motor disabil-
ity [5–8]. Recent reports described an expanding pheno-
type of laminin a2 deficiency with later onset which
shows slowly progressive weakness of limb-girdle mus-
cles. At least 25% of these patients achieve independent
ambulation and several patients with LAMA2 muta-
tions reveal normal MRI [9].
In general, the striking discrepancy between marked
white matter MRI signal alterations of cerebral white
matter and only subtle clinical signs of brain dysfunction
is well recognized. To date, the pathophysiology of the
white matter changes remains unclear. In this study, we
used localized proton magnetic resonance spectroscopy
(MRS) with absolute quantification of cerebral metabo-
lites to further characterize cerebral tissue abnormalities
in patients with MDC1A.Table 1
Clinical, immunohistochemical, and neuroradiological features in five patien
Patient 1 2
Sex M M
Affected sibling  
Age at onset Birth Bir
Max. motor milestone Walking Sit
Contractures + +
Head circumference (centile) at birth 75 n.a
Head circumference (centile) at MRS 90 75
Learning difficulties  
Epilepsy  +
Nerve conduction velocity n n
Highest CK level › ›
Age at biopsy 3w 1y,
Laminin a2 deficiency demonstrated in Muscle Mu
Degree of laminin a2 deficiency Near-comp. Co
MRI WM changes C P
Age at MRS 10m, 2y7m 7y2
M, male; CK, creatine kinase; ›, >100 U/L; ››, >1000 U/L; WM, white ma
near-complete; C, confluent; P, patchy.2. Patients and methods
We studied five boys with MDC1A whose ages
ranged from 10 months to 14 years at MRS. Table 1
summarizes the clinical, neuroradiological, and histolog-
ical features. In patients 1, 2, and 4, diagnosis of com-
plete or near-complete laminin a2 deficiency was based
on immunohistochemical investigations of a biopsy
from the quadriceps muscle. Muscle biopsies in patients
3 and 5 had been performed before immunohistochem-
istry for laminin a2 was available. In patient 3, laminin
a2 deficiency was demonstrated in an additional skin
biopsy. Immunocytochemical studies were performed
using antibodies to the 80 kDa fragment of merosin
(Anti-Human Merosin, Gibco-BRL, Berlin, Germany)
in patients 1, 2, 3, and 4. Additionally, a second
antibody (NCL Merosin, Novocastra, Newcastle-
upon-Tyne, UK) was used in patients 1, 2, and 3.
Laminin a2 deficiency was complete in patients 2 and
4, and near-complete in patients 1 and 3. Patient 5 was
included in this study as his clinical, neuroradiological,
and histological features clearly pointed to MDC1A.
Mutation analysis of the LAMA2 gene was not per-
formed in our patients, as this assay currently is not
readily available.
MRI revealed signal alterations of supratentorial
white matter in all patients to a varying degree. Diffuse
extensive widespread T2 hyperintensity of white matter
was present in patients 1 (Fig. 1), 4, and 5. White matter
appeared swollen in these patients, and head circumfer-
ence was at the 90th, 98th, and above the 98th centile,
respectively. Macrocephaly in patient 5 was present at
birth already. MRI in patients 2 and 3 showed patchy
T2 hyperintensities in supratentorial white matter that
were extensive and widespread in patient 2 (Fig. 2) and
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9y 3y 2m, 10y 6y
scle Skin Muscle n.a.
mplete Near-comp. Complete n.a.
P C C
m 9y6m 10y3m 14y4m
tter; +, present; , absent; n, normal; n.a., not available; near-comp.,
Fig. 1. Cerebral MRI and proton MRS of patient 1 with laminin a2 CMD at 10 months and 2 years 7 months of age. (A and D) T1-weighted MRI
and MRS (STEAM, TR/TE/TM = 6000/20/10 ms) of paramedian parietal gray matter, (B and E) T2-weighted MRI and MRS of left parieto-
occipital white matter at 10 months of age and (C and F) at 2 years and 7 months of age, respectively.
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the 98th centile, respectively. No overt cortical dysplasia
was present in any of the patients.Written informed consent was obtained from the
patients’ parents. Combined MRI/MRS studies were
carried out at 2.0 T (Siemens Magnetom Vision,
Fig. 2. Cerebral MRI and proton MRS of patient 2 with laminin a2 CMD at 7 years 2 months of age. (A) T2-weighted MRI and (B) MRS of right
parieto-occipital white matter.
Fig. 3. T2-wighted MRI (1.5 T) of patient 3 at 4 years of age showing
patchy white matter alterations.
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coil. Fully relaxed short-echo time proton MR spectra
were acquired by means of a single-voxel stimulated
echo acquisition mode (STEAM) localization sequence
(TR/TE/TM = 6000/20/10 ms, 64 accumulations) as
described previously [10]. Volumes of interest (VOI)
were selected from T1-weighted (3D FLASH) and T2-
weighted (FSE) images, with sizes ranging from 4.1 to
18 ml. VOI locations included one or two regions in
affected white matter (frontal, parieto-occipital) and
paramedian parietal grey matter in all patients. In addi-
tion, basal ganglia were examined in patient 4.
Spectral evaluation and quantification of absolute
metabolite concentrations were accomplished with use
of LCModel [11]. The approach represents a user-
independent fitting routine based on a library of
calibrated model spectra of individual compounds andtherefore avoids bias due to manual post-processing.
Because of the use of an external reference, the method
is free from putative changes of the internal water
proton signal. Moreover, the quantification is neither
compromised by T1 saturation (very long repetition
time) nor markedly affected by T2 attenuation (very
short echo time). Metabolite concentrations are there-
fore expressed in mM, i.e., mmol per liter VOI, without
corrections for CSF contributions and residual T2 relax-
ation effects. Major detectable metabolites include the
neuroaxonal markers [12] N-acetylaspartate and N-acet-
ylaspartylglutamate (tNAA), creatine, and phosphocre-
atine (tCr) as ubiquitous compounds linked to energy
metabolism [13], choline-containing compounds (Cho)
involved in membrane turnover [14], the glial (astrocyt-
ic) marker [15] myo-inositol (Ins), and lactate (Lac) as
the intermediate product of nonoxidative glucose con-
sumption. Previous studies of regional age dependencies
of cerebral metabolites provided age-matched controls
for the evaluation of individual pathological alterations
[16]. Values different from the mean normal value byP2
standard deviations (SD) were regarded as abnormal.
Further details of MRS data acquisition and spectral
evaluation have been described elsewhere [17].3. Results
Fig. 1 shows representative MR images and spectra
of grey and white matter of patient 1 with extensive
diffuse leukoencephalopathy at 10 months and 31
months of age. Fig. 2 shows a complementary image
and white matter spectrum of patient 2 with patchy
white matter alterations. Quantitative analyses of
absolute metabolite concentrations in white matter
are summarized in Table 2. Patient 3, who showed the
Table 3
Cerebral metabolite concentrations (mM) in grey matter and aged-matched controls [16]
Patient Age Regiona tNAA tCr Cho Ins Lac
1 10m PMP 7.7* 6.7 1.4 5.3 –
Control (<1 y, n = 6) 6.1 ± 0.7 5.5 ± 0.7 1.4 ± 0.3 4.8 ± 0.7 –
2y7m PMP 8.5 6.3 1.2 5.0 –
Control (2–<5 y, n = 16) 8.2 ± 0.9 6.4 ± 0.7 1.1 ± 0.2 4.7 ± 0.4 –
2 7y2m PMP 8.4 6.5 1.2 4.7 –
3 9y6m PMP 8.2 6.5 1.0 4.0 0.8
Control (5–<10 y, n = 13) 8.2 ± 0.9 6.2 ± 0.5 1.2 ± 0.2 4.6 ± 0.7 –
4 10y3m PMP 8.5 7.1 1.0 4.5 –
5 14y4m PMP 9.1 6.1 1.2 4.9 –
Control (10–18y, n= 22) 9.0 ± 0.8 6.5 ± 0.5 1.1 ± 0.2 4.3 ± 0.6 –
4 10y3m BG 6.4 6.8 1.2 3.8 –
Control (10–18y, n= 5) 8.0 ± 0.9 7.7 ± 0.9 1.8 ± 0.4 3.3 ± 0.8 –
*P2 SD from control.
a PMP: paramedian parietal, BG: basal ganglia.
Table 2
Cerebral metabolite concentrations (mM) in white matter and aged-matched controls [16]
Patient Age Regiona tNAA tCr Cho Ins Lac
1 10m LPO 3.6* 3.9* 1.3* 3.8 0.9
RPO 4.3* 3.9* 1.3* 3.9 1.0
Control (<1 y, n = 10) 6.2 ± 0.8 5.4 ± 0.5 2.0 ± 0.2 4.0 ± 0.5 –
2y7m LPO 4.3** 3.1** 1.3* 3.3 –
RF 3.5** 3.3** 1.3* 3.8 –
Control (2–<5 y, n = 12) 7.2 ± 0.7 5.0 ± 0.4 1.9 ± 0.2 3.7 ± 0.6 –
2 7y2m LF 5.4* 4.3 1.5 3.8 –
RPO 5.3* 3.9* 1.5 3.6 –
3 9y6m RPO 6.5 5.1 1.2 3.4 –
Control (5–<10 y, n = 7) 6.9 ± 0.6 4.9 ± 0.4 1.6 ± 0.3 3.7 ± 0.6 –
4 10y3m LPO 5.0** 3.2** 1.0* 3.5 –
RPO 5.6* 3.4* 1.2* 2.5 1.8
5 14y4m LPO 5.3** 2.9** 1.0* 2.2 –
RPO 4.8** 2.2** 0.8** 1.8 –
Control (10–18y, n= 12) 7.9 ± 0.6 4.8 ± 0.4 1.6 ± 0.2 3.9 ± 1.2 –
*P2 SD from control; **P4 SD from control.
a L, left; R, right; F, frontal; P, parietal; O, occipital.
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only one with all metabolites within the normal range.
In general, metabolic changes in white matter showed
a characteristic pattern consisting of a significant reduc-
tion of tNAA and tCr as well as a milder decrease of
Cho and normal Ins values. This profile was found in
at least one white matter region investigated in four of
five patients. The decreases of tNAA ranged from 2.2
to 5.3 SD of mean control, and tCr was reduced by 3
to 6.5 SD. A significant reduction of Cho by 2 to 4
SD was found in three patients, whereas patients 2
and 3 had a decrease of Cho by only 0.3 to 1.3 SD. In
contrast, Ins was normal in all patients in all 11 white
matter regions investigated. A slight increase of Lac
was observed in three of the examined white matter
regions.Quantitative MRS of cortical grey matter (all
patients) and basal ganglia (patient 4 only) revealed
metabolite concentrations within the normal range for
all metabolites (Table 3). The only exception was an
increased concentration of tNAA in cortical grey matter
of patient 1 at the time of his first investigation (age 10
months). At follow-up (2 years 7 months) the tNAA
level was within the normal range.4. Discussion
Using quantitative MRS in five patients with
MDC1A we detected most pronounced changes of
metabolites in cerebral white matter in those patients
with more extensive widespread and diffuse white matter
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contrast, MRS was normal (patient 3) or revealed
merely mild metabolite abnormalities (patient 2) in
both patients with only mild and patchy T2-hyperin-
tensities. On the other hand, MRS abnormalities did
not correlate to the severity of muscular weakness,
signs of cerebral dysfunction, or degree of laminin a2
deficiency, as evident from Table 1. In four patients
with white matter alterations on T2-weighted MRI a
consistent pattern of metabolite changes was detected
comprising decreases of tNAA, tCr, and to a milder
degree also of Cho. In contrast, Ins concentrations
were in the normal range. There are two possible
explanations for this metabolic profile. First, the alter-
ations are consistent with, but not specific for neuroax-
onal loss as suggested by the low levels of tNAA and
tCr. Alternatively, the same pattern may be the result
of a dilution of all metabolites, or more precisely of
a generally reduced cellular density, which is accompa-
nied by a relative astrocytic proliferation as indicated
by the preserved level of Ins.
The pathophysiology of white matter alterations in
MDC1A is not completely understood. Two lines of evi-
dence suggest an important role for laminin a2 in CNS
myelination and stability of cerebral whiter matter.
First, a leakage of water across the blood–brain barrier
has been presumed to result from laminin a2 deficiency.
In a study combining immunohistochemical and specific
electron microscopy techniques laminin a2 was localized
in the normal human brain to the basal lamina of all
cerebral blood vessels, whereas choroid plexus and men-
ingeal blood vessels showed no immunoreactivity [18].
This observation led to the hypothesis, that laminin a2
may be important for the selective filtration capacity
of the blood–brain barrier. Subsequently, it has been
postulated, that the lack of laminin a2 in cerebral vessels
of children with MDC1A may cause impaired selective
filtration, leading to leakage of plasma components
[18] and that the increased T2 relaxation time in MRI
may be attributed to increased water content in white
matter [19].
Second, recent investigations of oligodendrocyte
differentiation and myelin membrane formation in oli-
godendrocytes grown in cell culture showed that lami-
nin-2 substrates dramatically enhance myelin
membrane formation. This effect is probably mediated
via b1 integrins [20]. It has been concluded that laminin
a2 acts to enhance the production and spreading of the
developing myelin sheath along and around the axon
[20]. A critical role for laminin a2 in CNS myelination
has been demonstrated in laminin a2 deficient mice,
where a reduced thickness of the corpus callosum, a
reduction in the concentration of mature oligodendro-
cytes without a change in total glia cell concentration,
and defects in myelin lamellar compaction and sheath
thickness have been demonstrated [21].To our knowledge, histopathological investigations of
cerebral white matter lesions in immunohistochemically
proven MDC1A of humans are confined to two reports.
In an older study, a brain biopsy of a 14-year old girl
with a condition consistent with MDC1A showed intact
myelin sheaths but obvious astrocytic proliferation [22],
in line with the present MRS observations. An autopsy
study of a 4-month-old infant with merosin-deficient
CMD revealed polymicrogyria and occipital agyria with
marginal neuroglial heterotopia, but normal pattern of
myelination consistent with early age [8].
There are only two previous reports on the use of
MRS for a characterization of white matter alterations
in MDC1A, both based on a determination of metabo-
lite ratios. In a 4-year-old girl with MDC1A MRS of
affected white matter revealed a normal NAA/Cr ratio
and increased Cho/Cr and Ins/Cr ratios [23]. Similar
results may be obtained for the present study when the
quantitative metabolite concentrations are used to cal-
culate ratios thereof. For example, the mean tNAA/
tCr concentration ratio of patients 4 and 5 in right
and left white matter is 1.77 close to 1.65 obtained for
age-matched controls (compare Table 2). In a more
recent study using diffusion-weighted MRI and proton
MRS of altered white matter in nine children with
MDC1A the authors concluded that free-water concen-
trations are abnormally high in this condition [24]. This
finding was based on reduced ratios of NAA/H2O, Cr/
H2O, Cho/H2O, and Ins/H2O as well as on increased
values of the apparent diffusion coefficient. Again in
agreement with our results, MRS revealed normal
NAA/Cr and Cho/Cr as well as slightly increased Ins/
Cr metabolite ratios. Our findings extend these reports
because the determination of absolute metabolite con-
centrations allows for an unambiguous and specific
assignment of the observed alterations to individual
metabolites.
Macrocephaly in some patients and swelling of dif-
fuse T2 hyperintensities in MDC1A point to edema of
white matter. Reductions of the concentrations of most
major metabolites, as demonstrated in this study, are
consistent with white matter edema, if the normal con-
centrations of Ins are attributed to relative astrocytosis.
This interpretation is in agreement with the hypothesis
that laminin a2 deficiency results in leakage of fluids
across the blood–brain barrier. Interestingly, the white
matter alterations are not seen in compacted white mat-
ter such as the internal capsule or the corpus callosum.
This observation is consistent with an edema rather than
with a primary myelinopathy. Also the mild clinical
signs of white matter dysfunction argue against a
marked loss of vital neuroaxonal tissue.
We are not able to estimate the extent to which
impaired myelin membrane formation due to laminin
a2 deficiency may account for leukoencephalopathy in
MDC1A. Dominant hypomyelination, however, is asso-
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reported here, i.e. increased concentrations of tNAA,
tCr, and Ins together with a reduction of Cho as demon-
strated in Pelizaeus–Merzbacher disease [25].
Our finding of largely normal spectra in cortical and
subcortical grey matter is in line with the predominance
of alterations in white matter well known from MRI
studies of MDC1A. This difference is not explained by
the fluid leakage hypothesis, as laminin a2 is expressed
in the basal lamina of all cerebral blood vessels [18].
On the other hand, the relevance of laminin a2 for
CNS myelination has been demonstrated in laminin a2
deficient mice, where defects in myelin lamellar compac-
tion and sheath thickness have been observed [21]. We
speculate that laminin a2 deficiency might lead to a
locus minoris resistentiae in oligodendrocytes that facil-
itates leakage of water predominantly in white matter.
Clinical as well as MRI and MRS features of CNS
alteration in laminin a2 deficiency show considerable
overlap with those of megalencephalic leukoencephalop-
athy with subcortical cysts (MLC) [26,27]. Both condi-
tions share in common early macrocephaly, extensive
diffuse T2 hyperintensities of cerebral white matter that
appears swollen, relatively mild signs of cerebral dys-
function, and a metabolic pattern comprising reduced
tNAA, tCr, and Cho together with normal Ins. The
MRS profile of white matter in MLC is in good agree-
ment with the histopathological changes known to occur
in this condition [28]. Histopathology revealed a cavitat-
ing spongiform leukoencephalopathy with vacuoles in
the outermost lamellae of myelin sheaths. Subcortical
white matter was altered by intense fibrillary astroglio-
sis, myelinated axons were well preserved [29]. Canavan
disease (CD) is a further condition characterized by
macrocephaly and swollen white matter with marked
T2 hyperintensity. MRS in CD, however, shows highly
elevated tNAA due to a deficiency of aspartoacylase,
and an osmotic–hydrostatic mechanism resulting from
the continuous synthesis and efflux of NAA has been
proposed to be responsible for the CD phenotype [30].
In summary, the present results corroborate
previous views and provide additional insights in the
metabolic changes occurring in laminin a2 deficiency
in human brain. We emphasize the need for histopa-
thological investigations of white matter alterations
in MDC1A for a better understanding of the detailed
pathophysiology.References
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